Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals

Background—Substantial efforts over the past decade have increased rates of intravenous tissue plasminogen activator (tPA) use in the United States. We sought to determine changes in patient characteristics and rates of tPA use over time among hospitalized acute ischemic stroke (AIS) patients. Methods and Results—We analyzed all AIS patients (n=1 093 895) and those arriving ⩽2 hours and treated with tPA ⩽3 hours after onset (n=50 798) from 2003 to 2011 in the American Heart Association’s Get with the Guideline–Stroke (GWTG–Stroke). Categorical data were analyzed by Pearson &khgr;2 and continuous data by Wilcoxon test. Intravenous tPA use ⩽3 hours after onset increased from 4.0% to 7.0% in all AIS admissions and 42.6% to 77.0% in AIS patients arriving ⩽2 hours and fully eligible for tPA (P<0.001). In univariate analysis, tPA use increased over time, especially in those aged >85 years, nonwhite, and with milder strokes (National Institutes of Health Stroke Scale 0–4). Door-to-image time (median 24 versus 20 minutes) and door-to-tPA time (median 81 versus 72 minutes) also improved, with ≈65% of tPA-treated patients getting brain imaging ⩽25 minutes after arrival. Multivariable analysis showed that with each additional calendar year, the odds that an eligible patient would receive tPA increased by 1.37-fold, adjusting for other covariates. Conclusions—The frequency of IV tPA use among all AIS patients, regardless of contraindications, nearly doubled from 2003 to 2011. Treatment with tPA has expanded to include more patients with mild deficits, nonwhite race/ethnicity, and oldest old age.

[1]  E. Peterson,et al.  Patterns of Emergency Medical Services Use and Its Association With Timely Stroke Treatment: Findings From Get With the Guidelines-Stroke , 2013, Circulation. Cardiovascular quality and outcomes.

[2]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[3]  Eric E. Smith,et al.  Times From Symptom Onset to Hospital Arrival in the Get With The Guidelines–Stroke Program 2002 to 2009: Temporal Trends and Implications , 2012, Stroke.

[4]  Eric E. Smith,et al.  Predictors of Rapid Brain Imaging in Acute Stroke: Analysis of the Get With The Guidelines–Stroke Program , 2012, Stroke.

[5]  R. Marshall,et al.  Safety of Thrombolysis in Patients Over the Age of 80 , 2012, The neurologist.

[6]  Jiguang Wang,et al.  Factors Associated With Prehospital Delays in the Presentation of Acute Stroke in Urban China , 2012, Stroke.

[7]  Eric E. Smith,et al.  Improving Door-to-Needle Times in Acute Ischemic Stroke: The Design and Rationale for the American Heart Association/American Stroke Association's Target Stroke Initiative , 2011, Stroke.

[8]  Dawn Kleindorfer,et al.  Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States: A Doubling of Treatment Rates Over the Course of 5 Years , 2011, Stroke.

[9]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[10]  Eric E. Smith,et al.  Hospital-Level Variation in Mortality and Rehospitalization for Medicare Beneficiaries With Acute Ischemic Stroke , 2011, Stroke.

[11]  D. Cutler,et al.  Trends in thrombolytic use for ischemic stroke in the United States. , 2010, Journal of hospital medicine.

[12]  R. Sacco,et al.  Translating Evidence Into Practice: A Decade of Efforts by the American Heart Association/American Stroke Association to Reduce Death and Disability Due to Stroke: A Presidential Advisory From the American Heart Association/American Stroke Association , 2010, Stroke.

[13]  Eric E. Smith,et al.  Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke , 2010, Circulation. Cardiovascular quality and outcomes.

[14]  Xin Tong,et al.  Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007. , 2009, Morbidity and mortality weekly report. Surveillance summaries.

[15]  J. Zivin,et al.  Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Administration (FDA) , 2009, Annals of neurology.

[16]  Li Liang,et al.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.

[17]  Eric E. Smith,et al.  Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke , 2005, Stroke.

[18]  A. Divani,et al.  Thrombolysis for Ischemic Stroke in the United States: Data from National Hospital Discharge Survey 1999-2001 , 2005, Neurosurgery.

[19]  Michael D Hill,et al.  tPA use for Stroke in the Registry of the Canadian Stroke Network , 2005, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[20]  Peter Moyer,et al.  Recommendations for the Establishment of Stroke Systems of Care: Recommendations From the American Stroke Association’s Task Force on the Development of Stroke Systems , 2005, Circulation.

[21]  California Acute Stroke Pilot Registry Investigators Prioritizing interventions to improve rates of thrombolysis for ischemic stroke , 2005 .

[22]  M. Hammer,et al.  Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. , 2004, Archives of neurology.

[23]  Joseph P Broderick,et al.  Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study , 2004, Stroke.

[24]  A. Demchuk,et al.  Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. , 2001 .

[25]  A. Furlan,et al.  Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. , 2000, JAMA.

[26]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[27]  Vl Roger,et al.  American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update : a report from the American Heart Association , 2011 .